Does OKT3 increase the risk of recurrent hepatitis B in patients transplanted for hepatitis B?
Chu
C J
CJ
Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Box 0362, Ann Arbor, MI 48109, USA.
Lok
A S
AS
D004279:DNA, Viral / Q000032:analysis; D006084:Graft Rejection / Q000188:drug therapy*; D006509:Hepatitis B / Q000601:surgery* / Q000821:virology; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006515:Hepatitis B virus / Q000235:genetics / Q000276:immunology; D006801:Humans; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016031:Liver Transplantation; D016853:Muromonab-CD3 / Q000009:adverse effects*; D012008:Recurrence; D012307:Risk Factors
D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D007136:Immunoglobulins; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; C045213:hepatitis B hyperimmune globulin